Tandem Diabetes Care (NASDAQ:TNDM) Price Target Increased to $40.00 by Analysts at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) had its target price boosted by stock analysts at Stifel Nicolaus from $37.00 to $40.00 in a report released on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the medical device company's stock. Stifel Nicolaus' target price points to a potential upside of 14.38% from the company's previous close.

TNDM has been the subject of a number of other research reports. Citigroup raised their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 3rd. StockNews.com upgraded Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, Tandem Diabetes Care has an average rating of "Hold" and a consensus target price of $37.27.

Tandem Diabetes Care Stock Up 10.2 %

Shares of TNDM traded up $3.24 during midday trading on Tuesday, hitting $34.97. 2,429,976 shares of the company's stock traded hands, compared to its average volume of 1,744,879. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The firm's fifty day moving average is $30.09 and its 200-day moving average is $25.00. The company has a current ratio of 3.83, a quick ratio of 3.02 and a debt-to-equity ratio of 0.91. The stock has a market capitalization of $2.26 billion, a price-to-earnings ratio of -10.17 and a beta of 1.11.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The business had revenue of $196.80 million for the quarter, compared to analysts' expectations of $204.86 million. As a group, sell-side analysts anticipate that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

Hedge funds have recently made changes to their positions in the company. Eminence Capital LP increased its holdings in shares of Tandem Diabetes Care by 76.1% in the third quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company's stock valued at $114,028,000 after purchasing an additional 2,372,458 shares during the last quarter. Raymond James & Associates boosted its position in shares of Tandem Diabetes Care by 128.5% during the fourth quarter. Raymond James & Associates now owns 91,985 shares of the medical device company's stock worth $2,721,000 after buying an additional 51,721 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Tandem Diabetes Care by 4.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 367,011 shares of the medical device company's stock valued at $7,623,000 after acquiring an additional 16,586 shares in the last quarter. Paradice Investment Management LLC raised its stake in Tandem Diabetes Care by 23.9% in the third quarter. Paradice Investment Management LLC now owns 1,520,065 shares of the medical device company's stock valued at $31,572,000 after buying an additional 293,250 shares in the last quarter. Finally, Banque Pictet & Cie SA acquired a new stake in shares of Tandem Diabetes Care during the third quarter worth about $2,295,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.